<DOC>
	<DOCNO>NCT00679536</DOCNO>
	<brief_summary>The study propose use Fludarabine , Busulfan , Anti Thymocyte Globulin Rabbit ( ATG ) Total Body Irradiation preparative regimen hematopoietic stem cell transplant unrelated donor peripheral blood stem cell ( PBSC ) . The hypothesis state 100 day mortality type transplant significantly accept standard , 30 % unrelated donor .</brief_summary>
	<brief_title>Allogeneic Transplantation Pediatric Leukemias With Unrelated Donors</brief_title>
	<detailed_description>The primary objective study evaluate toxicity ( measured 100 day survival ) hematopoietic stem cell transplant unrelated donor novel preparative regimen Fludarabine , Busulfan , Anti-Thymocyte Globulin , Total Body Irradiation pediatric patient leukemia . The secondary objective evaluate relapse-free overall survival hematopoietic stem cell transplant well evaluate incidence acute chronic graft-versus-host disease preparative regimen .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>Ages 021 AML one follow stage : Having precede myelodysplasia ( MDS ) High Risk cytogenetics Requiring &gt; 2 cycle chemotherapy obtain complete remission High allelic ratio FLT3/ITD+ , Standard risk cytogenetics positive MRD end Induction Second great CR First relapse &lt; 25 % blast bone marrow With therapyrelated AML whose prior malignancy remission least 12 month ALL one follow stage : High risk first remission , define : Ph+ ALL ; , MLL rearrangement slow early response [ define M2 ( 525 % blast ) M3 ( &gt; 25 % blast bone marrow examination Day 14 induction therapy ) ] ; , Hypodiploidy ( &lt; 44 chromosome DNA index &lt; 0.81 ) ; , End induction M3 bone marrow ; , End induction M2 marrow MRD &gt; 1 % M23 marrow MRD &gt; 1 % Day 42 . Highrisk infant ALL define age &lt; 6 month diagnosis MLL ( 11q23 ) translocation . High risk second remission , define : Bone marrow relapse &lt; 36 month induction ; &gt; 36 mths match sibling donor available Tlineage relapse time ; , Very early isolated CNS relapse ( &lt; 18 month diagnosis ) ; , Slow reinduction ( M23 Day 28 ) relapse time . âˆ’ Any third subsequent CR . Biphenotypic undifferentiated leukemia CR first relapse must &lt; 25 % blast bone marrow MDS stage ; prior therapy allow CML chronic accelerate phase ; prior therapy allow Patient also must follow organ requirement : Adequate renal function define serum creatinine &lt; 2x normal , creatinine clearance &gt; 40 ml/min/m^2 70 ml/min . Adequate liver function define total bilirubin less equal 2 time normal AST ALT less equal 4 time normal . Adequate cardiac function define : shortening fraction &gt; 24 % echocardiogram , ejection fraction &gt; 30 % radionuclide angiogram . Adequate pulmonary function define DLCO , FEV1/FVC &gt; 60 % pulmonary function test . For child uncooperative PFTs evidence dyspnea rest exercise intolerance , pulse oximetry &gt; 94 % room air consider acceptable , normal chest xray . Adequate venous access ; double lumen central vascular access device equivalent additional PICC line require patient . Women childbearing potential sexually active male use effective contraception study . Inability give inform consent assent Inability obtain suitable donor Patient HIVpositive Patient active Hepatitis B Patient pregnant Patient otherwise consider unsuitable transplant discretion principal investigator .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Reduced Toxicity</keyword>
	<keyword>Toxicity</keyword>
	<keyword>Event Free Survival</keyword>
	<keyword>Graft v Host Disease</keyword>
</DOC>